Parvovirus B19 (B19) DNA was detected by dot blot hybridization in sera from 5 (17%) of 30 human immunodeficiency virus (HIV)-infected patients with hematocrits (HCT) of £24 and 4 (31%) of 13 HIV-infected patients with HCT of £20, suggesting that B19 is a reasonably common cause of severe anemia in HIV infection. The anemia promptly remitted after immunoglobulin therapy in 3 of 4 treated patients. The presence of IgM to B19, the clinical circumstance in which anemia developed, and the marrow morphology were poor predictors of chronic B19 infection. DNA hybridization studies of sera from 191 HIV-infected and 117 HIV-seronegative homosexual males attending a clinic in the Seattle area revealed that 1 (0.5%) and 2 (2%) samples, respectively, from the 2 groups contained B19. However, when assayed by polymerase chain reaction (PCR), 5% of the serum samples from HIVinfected persons and 9% from uninfected persons contained B19, although each had an HCT of §40. The data argue that anemia results from chronic high-titer B19 infection. Although a negative PCR assay excludes this diagnosis, DNA hybridization may be the more specific serum test. of B19 viremia in HIV-infected and high-risk individuals.
Chronic B19 viremia is a treatable cause of anemia [2, 3] ; hybridization, and marrow specimens were reviewed if available.
therefore, its diagnosis is important. However, the prevalence Clinical information was obtained from the medical records of of B19 viremia in anemic HIV-infected patients is not clear patients with positive B19 DNA test results 2-3 months and 3-5 years after the patient's initial assessment. [4] [5] [6] , and clinical guidelines have not been established. of B19 viremia in HIV-infected and high-risk individuals.
Virologic methods. Serum (5 mL) was analyzed for B19 DNA by dot blot hybridization [2] using a B19-specific probe (pYT103 plasmid fragment; gift of P. Tattersall, Yale University School of
Methods
Medicine, New Haven, CT). For polymerase chain reaction (PCR), Patient selection. All HIV-infected patients with significant DNA was extracted from serum (50 mL) by use of silica [7] , and anemia (HCT £24) who were evaluated between 1991 and 1993 an aliquot (10 mL) was tested for the presence of B19 by singleround PCR [8] using 50 mmol of primer pair M (nt 1419-1435) [9] and L (nt 2139-2123) in a reaction mix of 100 mL. The product was assayed by Southern hybridization using a 32 P-labeled probe Received 13 December 1996; revised 21 February 1997. generated by double digesting pYT103 with XmnI/XmaI restriction fied from marrow aspirate slides as described in [10] . B19-specific antibodies were tested by IgM and IgG immunocapIn 5 (17%) of the 30 patients, B19 infection was documented ture RIA [11] . Values were considered positive if ú3 arbitrary units by serum dot blot hybridization or by PCR amplification of (AU), equivocal if 1-3 AU, and negative if õ1 AU. Later, B19-DNA on marrow aspirate slides. If an HCT of £20 was the specific IgG was detected by ELISA using baculovirus-derived rediagnostic criterion, then 4 (31%) of 13 patients were detercombinant B19 capsids as antigen (Biotrin International, Dublin), mined to be infected with B19. Serologic analyses (i.e., an and results were recorded as negative (õ1) tion only in patient A14. Most B19 DNA-positive patients (i.e., A22, A23, and A24) had serum IgM and IgG levels of õ1 AU, which is consistent with an absent or delayed immunologic Results response. There was also a lack of correlation between laboraProspective studies of HIV-infected patients with anemia.
tory data (e.g., CD4 cell count, the presence or absence of The results of the prospective studies of 30 HIV-infected paother cytopenias, and the mean cell volume of red cells) and tients (coded A1-A30) with anemia are shown in table 1. All B19 viremia. Similarly, as shown in table 2, the clinical circumpatients except A1 were male. The risk factors for acquisition stance in which anemia developed did not predict which paof HIV were homosexuality (25 patients), injection drug use tients had B19. (4 patients), and perinatal transfusion (patient A12) and reAlthough not a component of this study, marrow aspirates flected the distribution of risk factors reported by HIV-infected and biopsies were obtained by the primary physician of 4 of patients in the Seattle community [12] . The patients ranged in the 5 patients viremic with B19. In 2 of the aspirates (from patients A24 and A29), the morphology showed pure red cell age from 10-53 years (median, 37). aplasia (PRCA), as hemoglobinized cells comprised õ5% of
The anemia improved but did not remit in patient A22. Two months after immunoglobulin administration, the B19 the nucleated cell population. In the marrow of patient A24, DNA dot blot was negative, and IgM and IgG antibody inmany proerythroblasts (early unhemoglobinized red cell precreased to 8.6 and 15 AU, respectively, suggesting an immucursors) were seen, and giant proerythroblasts, which are connologic clearance of B19. The patient died 9 months later of sidered pathognomonic for B19 infection [3], were prominent.
progressive AIDS. Perhaps his poor overall condition as well The 2 other marrow aspirates (from patients A22 and A23), as multiple coexistent factors (e.g., cachexia, dapsone, and however, did not fulfill criteria for PRCA. The ratio of hemocandidiasis) contributed to his anemia. During the patient's globinized cells to total marrow cells was 0.1 and 0.4, respeclast 6 months of life, his HCT was maintained at 26 -30 with tively. Each marrow aspirate had abnormalities, such as megaerythropoietin (8000 U 3 times each week subcutaneously; loblastic erythropoiesis, excess plasma cells, and the baseline erythropoietin level Å 70 mU/mL). inflammatory block of iron utilization, which are common in Prevalence of B19 viremia among homosexual men. To HIV-infected persons [1] .
determine the prevalence of B19 viremia in the male homoMarrow specimens were also reviewed from 7 patients sexual community in the Seattle area during 1990 -1991, sera without B19 viremia. Patient A2, who developed anemia 4
were obtained from 191 HIV-infected and 117 HIV-seronegamonths after beginning zidovudine therapy, was particularly tive (controls) homosexual males attending the AIDS Preveninstructive. Because his neutrophil count and platelet count tion Project clinic. The sera from 42% of the HIV-infected (296,000/mL) did not fall from their baseline values and his subjects and 62% of the controls contained IgG to B19. Only mean red cell volume remained at 86, zidovudine toxicity was 1 patient in each group had an IgM value in the positive not initially suspected to be the cause of this patient's severe range. Dot blot hybridization and PCR analyses were negative anemia (HCT Å 17). His marrow showed a block in erythroid for B19 DNA in these 2 individuals. differentiation at the level of proerythroblasts, hemogloWhen B19 viremia was assayed by dot blot hybridization, binized cells comprised 1% of the nucleated cell population, samples from 1 HIV-infected (0.5%) and 2 HIV-seronegative and giant proerythroblasts were abundant. However, dot blot (2%) subjects were positive. As IgG to B19 was negative (õ1 and PCR studies failed to demonstrate the presence of B19 AU) in each individual, the data suggest a 1% incidence of DNA, and serologic studies (a positive B19 IgG and negative B19 infection during the time of these analyses. The HIV-B19 IgM) suggested prior B19 exposure but not recent or infected patient's HCT was 40 when initial studies were done persisting disease. The anemia remitted with the discontinuaand remained at 38 -40 in subsequent determinations over the tion of zidovudine and recurred with rechallenge. Thus, marnext year. His CD4 cell count was 627 1 10 7 /L. row morphology can be misleading in the HIV-seropositive In contrast to results by dot blot hybridization, 4 (5%) of 77 patient population.
randomly selected samples from HIV-infected patients were Response to immunoglobulin therapy. Of 5 B19-viremic positive for B19 DNA when individually analyzed by PCR, patients, 4 received immunoglobulin therapy (400 mg/kg/day and 5 (9%) of 54 control samples were positive (not signifiintravenously for 5 days). All were transfusion-dependent for cantly different from HIV-infected individuals; P Å .5, Fish-ú5 months at the time of immunoglobulin administration.
er's exact test). The individuals with B19 DNA had HCTs of The anemia remitted (HCT §30) within 3 -4 weeks in 3 §40 in the community-based study. individuals. This remission was durable, lasting 3 -4 years Discussion (patients A24 and A29), or could be maintained by retreatment with immunoglobulin at 6-to 8-month intervals (patient A14).
Parvovirus B19 is a small (5.5 kb), stable, single-stranded DNA virus. Infection is associated with erythema infectiosum Thus, immunoglobulin therapy was likely cost-effective.
(fifth disease), spontaneous abortion, rheumatoid-like arthritis, B19 infects and lyses early erythroid precursors, a morphology of PRCA is expected [2, 3] , and giant proerythroblasts have and transient aplastic crisis (in patients with hemolysis) [3] . B19 enters erythroid precursor cells via the blood group P been considered a pathognomonic finding [3] . In our studies, marrow from 2 of 4 patients with B19 viremia did not have antigen, replicates extensively, and lyses its host cell. In an immunocompromised person, high-titer infection may persist, PRCA morphology. Marrow from patient A2 whose anemia resulted from zidovudine exposure (not B19) had classic giant leading to a chronic impairment of erythropoiesis. The life span of a circulating red blood cell is 120 days; therefore, a proproerythroblasts. Taken together, these results suggest that marrow morphology is neither sensitive nor specific for diagnosing longed suppression of erythropoiesis is required for anemia. B19-induced anemia has been described in children with conchronic B19 infection in patients infected with HIV.
In conclusion, we recommend that serum from HIV-infected genital immunodeficiency and acute lymphoblastic leukemia and in patients with HIV [3] .
patients with severe anemia be tested for B19 DNA by dot blot hybridization. This is especially indicated if the anemia persists B19 is a common infection: Ç50% of the adult population has IgG antibodies to B19, suggesting prior virus exposure. It after discontinuation of relevant medications or the resolution of coexistent infection or lymphoma. is endemic in communities of Europe, North America, and Asia [3, 13] . Epidemic spread is also common [3] . Because serum from most adults contains antibody to B19, commer-Effects of vitamin E (E) supplementation on influenza infection were examined in young and old C57BL/6NIA mice fed 30 or 500 ppm of E for 6 weeks and subsequently infected with influenza A/Port Chalmers/1/73 (H3N2). Old mice fed 30 ppm of E had significantly higher lung virus titers on days 2 and 7 after infection than young mice fed 30 ppm of E. Titers on all 3 days were significantly lower in old mice fed 500 ppm of E than in those fed 30 ppm. Significant effects of E on lung virus titers in young mice were observed on only day 5, but E caused more reduction of virus titers in old than in young mice (25-fold vs. 15-fold). An age-associated decline in NK cell activity was restored by 500 ppm of E in old but not young mice. Pulmonary cytotoxic T lymphocyte activity on day 7 was not affected by age or E. These experiments demonstrate that high doses of E significantly enhance influenza viral clearance in aged mice but only modestly affect young mice.
Infections, particularly those affecting the respiratory sysease [2] . Other immune functions that appear to aid in recovery from influenza include NK cell activity, high titers of neutraliztem, rank among the leading causes of death in older adults ing serum antibody, and, possibly, mucosal IgA [2] . [1] . Like humans, aged mice have more severe disease with Influenza infection in mice causes a decrease in lung and an influenza infection [2] , and most of our knowledge of the liver levels of the antioxidant nutrients [3] . One of the biologic pathogenesis of and the host defenses against influenza was changes associated with aging is a decrease in antioxidant defirst established in mice and later confirmed in humans [2] . fense status, which results in increased free radical formation Many factors contribute to recovery from influenza infection. and lipid peroxidation. Increased lipid peroxidation, including The most important is cellular immunity, in particular antiinthat of prostaglandin E 2 (PGE 2 ) production, has been implicated fluenza cytotoxic T lymphocyte (CTL) activity. In aged mice, in the age-associated dysregulation of cytokine production and lower CTL activity correlates with prolonged duration of disdecrease in lymphocyte proliferation and CTL and NK cell activity [4] . Influenza infection is associated with the release of a variety of cytokines and eicosanoids in mice [5] . Received 5 August 1996; revised 2 December 1996. Vitamin E supplementation increases delayed-type hyperAll conditions and handling of the animals were approved by the Animal sensitivity skin response, T cell proliferation, and interleukin 
